FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:924-933 March 2, 2006 Number 9 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Ropper, A. H. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Progressive multifocal leukoencephalopathy (PML) was reported to have developed in three patients treated with natalizumab. We conducted an evaluation to determine whether PML had developed in any other treated patients.

Methods We invited patients who had participated in clinical trials in which they received recent or long-term treatment with natalizumab for multiple sclerosis, Crohn's disease, or rheumatoid arthritis to participate. The clinical history, physical examination, brain magnetic resonance imaging (MRI), and testing of cerebrospinal fluid for JC virus DNA were used by an expert panel to evaluate patients for PML. We estimated the risk of PML in patients who completed at least a clinical examination for PML or had an MRI.

Results Of 3417 patients who had recently received natalizumab while participating in clinical trials, 3116 (91 percent) who were exposed to a mean of 17.9 monthly doses underwent evaluation for PML. Of these, 44 patients were referred to the expert panel because of clinical findings of possible PML, abnormalities on MRI, or a high plasma viral load of JC virus. No patient had detectable JC virus DNA in the cerebrospinal fluid. PML was ruled out in 43 of the 44 patients, but it could not be ruled out in one patient who had multiple sclerosis and progression of neurologic disease because data on cerebrospinal fluid testing and follow-up MRI were not available. Only the three previously reported cases of PML were confirmed (1.0 per 1000 treated patients; 95 percent confidence interval, 0.2 to 2.8 per 1000).

Conclusions A detailed review of possible cases of PML in patients exposed to natalizumab found no new cases and suggested a risk of PML of roughly 1 in 1000 patients treated with natalizumab for a mean of 17.9 months. The risk associated with longer treatment is not known.

Source Information

From the Institute of Neurology, Queen Square, London (T.A.Y., K.M., H.R.J.); the Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), Bethesda, Md. (E.O.M., C.R., J.H., B.C.); the Department of Laboratory Medicine, NIH Clinical Center, Bethesda, Md. (G.F., S.F.); the Department of Neuroradiology, University of Basel, Basel, Switzerland (N.M.-L., E.-W.R.); the Department of Radiology, Vrije Universiteit Medical Centre, Amsterdam (E.S., F.B.); and the Departments of Neurology and Medicine, School of Medicine, Washington University, St. Louis (D.B.C.).

Drs. Yousry, Major, and Clifford contributed equally to this article.

Address reprint requests to Dr. Major at the Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, NIH, 10 Center Dr., Bldg. 10, Rm. 3B14, Bethesda, MD 20892-1296, or at majorg{at}ninds.nih.gov.

Full Text of this Article

Related Letters:

Natalizumab for Relapsing Multiple Sclerosis
Tenser R. B., Jeffery D. R., Meyer M. A., Polman C. H., Rudick R. A., Major E. O., Yousry T. A., Clifford D. B., Ropper A. H.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:2387-2389, Jun 1, 2006. Correspondence

This article has been cited by other articles:

• Ravichandran, V., Major, E. O. (2008). DNA-binding transcription factor NF-1A negatively regulates JC virus multiplication. J. Gen. Virol. 89: 1396-1401 [Abstract] [Full Text]  
• Vellinga, M. M., Castelijns, J. A., Barkhof, F., Uitdehaag, B.M.J., Polman, C. H. (2008). POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS. Neurology 70: 1150-1151 [Full Text]  
• Verschoor, E. J., Groenewoud, M. J., Fagrouch, Z., Kewalapat, A., van Gessel, S., Kik, M. J. L., Heeney, J. L. (2008). Molecular characterization of the first polyomavirus from a New World primate: squirrel monkey polyomavirus. J. Gen. Virol. 89: 130-137 [Abstract] [Full Text]  
• SMITH, D. J., VAINIO, P. J. (2007). Targeting Vascular Adhesion Protein-1 to Treat Autoimmune and Inflammatory Diseases. Ann. N. Y. Acad. Sci. 1110: 382-388 [Abstract] [Full Text]  
• Sabroe, I., Parker, L. C, Calverley, P. M A, Dower, S. K, Whyte, M. K B (2007). Pathological networking: a new approach to understanding COPD. Thorax 62: 733-738 [Abstract] [Full Text]  
• Ransohoff, R. M. (2007). Natalizumab for Multiple Sclerosis. NEJM 356: 2622-2629 [Full Text]  
• Ross, A. P. (2007). Treatment strategies across the multiple sclerosis lifespan. Neurology 68: S1-S2 [Full Text]  
• Alvarez-Lafuente, R., Garcia-Montojo, M., De Las Heras, V., Bartolome, M., Arroyo, R. (2007). JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event. Mult Scler 13: 590-595 [Abstract]  
• Zandi, M. S, Coles, A. J (2007). Notes on the kidney and its diseases for the neurologist. J. Neurol. Neurosurg. Psychiatry 78: 444-449 [Abstract] [Full Text]  
• D'Haens, G. (2007). Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 56: 725-732 [Full Text]  
• Dorsey, E. R., Thompson, J. P., Noyes, K., Dick, A. W., Holloway, R. G., Schwid, S. R. (2007). Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology 68: 1524-1528 [Abstract] [Full Text]  
• Owczarczyk, K., Hilker, R., Brunn, A., Hallek, M., Rubbert, A. (2007). Progressive multifocal leucoencephalopathy in a patient with sarcoidosis--successful treatment with cidofovir and mirtazapine. Rheumatology (Oxford) 46: 888-890 [Full Text]  
• Balcer, L. J., Galetta, S. L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F. D., Miller, D. H., O'Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E. -W., Rudick, R. A., Stuart, W. H., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., for the AFFIRM and SENTINEL Investigators, (2007). Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68: 1299-1304 [Abstract] [Full Text]  
• Sweet, B. V. (2007). Natalizumab update. Am J Health Syst Pharm 64: 705-716 [Abstract] [Full Text]  
• Khalili, K., White, M. K., Lublin, F., Ferrante, P., Berger, J. R. (2007). Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 68: 985-990 [Abstract] [Full Text]  
• Stuve, O., Marra, C. M., Cravens, P. D., Singh, M. P., Hu, W., Lovett-Racke, A., Monson, N. L., Phillips, J. T., Tervaert, J. W. C., Nash, R. A., Hartung, H.-P., Kieseier, B. C., Racke, M. M., Frohman, E. M., Hemmer, B. (2007). Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions. Arch Neurol 64: 169-176 [Abstract] [Full Text]  
• Johnston, S. L (2007). Biologic therapies: what and when?. J. Clin. Pathol. 60: 8-17 [Abstract] [Full Text]  
• Berger, J R (2006). Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 65: iii48-iii53 [Abstract] [Full Text]  
• Lederman, M. M., Penn-Nicholson, A., Cho, M., Mosier, D. (2006). Biology of CCR5 and its role in HIV infection and treatment.. JAMA 296: 815-826 [Abstract] [Full Text]  
• Gold, R., Hohlfeld, R. (2006). Multiple sclerosis therapy: new agents carry new risks. PN 6: 248-251 [Full Text]  
• Friese, M. A., Montalban, X., Willcox, N., Bell, J. I., Martin, R., Fugger, L. (2006). The value of animal models for drug development in multiple sclerosis. Brain 129: 1940-1952 [Abstract] [Full Text]  
• Tenser, R. B., Jeffery, D. R., Meyer, M. A., Polman, C. H., Rudick, R. A., Major, E. O., Yousry, T. A., Clifford, D. B., Ropper, A. H. (2006). Natalizumab for relapsing multiple sclerosis.. NEJM 354: 2387-2389 [Full Text]  
• (2006). Risk for PML with Natalizumab. JWatch Infect. Diseases 2006: 5-5 [Full Text]  
• (2006). Promise and Peril of Natalizumab for MS. JWatch General 2006: 3-3 [Full Text]  
• Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M. A., Sandrock, A. W., the AFFIRM Investigators, (2006). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.. NEJM 354: 899-910 [Abstract] [Full Text]  
• Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., Sandrock, A. W., the SENTINEL Investigators, (2006). Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.. NEJM 354: 911-923 [Abstract] [Full Text]  
• Ropper, A. H. (2006). Selective treatment of multiple sclerosis.. NEJM 354: 965-967 [Full Text]